In an era when Washington seems incapable of finding common ground on virtually any issue, it’s notable to encounter a policy area where stakeholders across the political spectrum agree. Gene ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

SAN FRANCISCO, Feb 4 (Reuters) - Two U.S. senators this week introduced a bill that would create new rules around the sale of ...

An expanded synthetic biology platform enables the assembly of long, high-complexity DNA sequences, reducing technical barriers and supporting next-generation research in medicine, vaccines, and ...

New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market SAN CARLOS, ...

Genetic medicines such as cell and gene therapies and mRNA vaccines offer extraordinary promise for treating a variety of diseases, including genetic disorders, cancer, and autoimmune diseases. These ...

Johnson and Alistar competed as finalists in CU Boulder’s 2025 Lab Venture Challenge where their technology generated much interest from industry leaders. Access to DNA is crucial in many branches of ...

The next great biological threat may not begin in a wet market, a jungle, or a laboratory accident. It may begin on a laptop ...

In today’s competitive biotechnology landscape, control and speed define success for companies and core labs producing synthetic genes. Yet many gene synthesis teams still rely on outsourced oligo ...